CYTOMX THERAPEUTICS INC. - COMMON STOCK

CytomX Therapeutics to Present at Upcoming Virtual August Investor Conferences

03 авг 2022 07:00:02 Источник Nasdaq GlobeNewswire

CytomX Therapeutics to Report Second Quarter 2022 Financial Results on August 4, 2022

28 июл 2022 07:00:01 Источник Nasdaq GlobeNewswire

CytomX Therapeutics Provides Strategic Update

13 июл 2022 15:05:00 Источник Nasdaq GlobeNewswire

CytomX Therapeutics Announces Phase 2 Results for Praluzatamab Ravtansine in Breast Cancer

06 июл 2022 15:05:00 Источник Nasdaq GlobeNewswire

CytomX Therapeutics Announces New Employment Inducement Grants

16 июн 2022 07:00:01 Источник Nasdaq GlobeNewswire

CytomX Therapeutics to Present at Jefferies 2022 Global Healthcare Conference

01 июн 2022 07:00:01 Источник Nasdaq GlobeNewswire

CytomX Therapeutics Announces First Patient Dosed with CX-904 in Phase 1 Study in Patients with Advanced Solid Tumors

26 май 2022 07:00:00 Источник Nasdaq GlobeNewswire

CytomX Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

05 май 2022 15:15:00 Источник Nasdaq GlobeNewswire

CytomX Therapeutics to Report First Quarter 2022 Financial Results on May 5, 2022

28 апр 2022 07:00:02 Источник Nasdaq GlobeNewswire

CytomX Therapeutics Announces Retirement of John A. Scarlett, M.D. from Board of Directors

14 апр 2022 15:15:00 Источник Nasdaq GlobeNewswire

CytomX Therapeutics Announces Retirement of Frederick W. Gluck from Board of Directors

23 мар 2022 15:15:00 Источник Nasdaq GlobeNewswire

CytomX Therapeutics to Present Updated Preclinical Data for Conditionally Activated Cytokine Program at AACR Annual Meeting 2022

17 мар 2022 07:00:01 Источник Nasdaq GlobeNewswire

CytomX Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results, and Provides Business Update

01 мар 2022 15:15:00 Источник Nasdaq GlobeNewswire

CytomX Therapeutics to Present at Cowen 42nd Annual Healthcare Conference

28 фев 2022 07:00:01 Источник Nasdaq GlobeNewswire

CytomX Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022

22 фев 2022 07:00:02 Источник Nasdaq GlobeNewswire

CytomX Therapeutics Announces New Employment Inducement Grants

16 фев 2022 07:00:01 Источник Nasdaq GlobeNewswire

CytomX Therapeutics Announces Promotion of Amy C. Peterson, M.D. to President and Chief Operating Officer

07 фев 2022 08:00:01 Источник Nasdaq GlobeNewswire

CytomX Therapeutics Announces FDA Clearance of Investigational New Drug Application for CX-904 for the Treatment of Advanced Solid Tumors

19 янв 2022 07:00:01 Источник Nasdaq GlobeNewswire

CytomX Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

05 янв 2022 07:00:03 Источник Nasdaq GlobeNewswire

CytomX Therapeutics Announces Preliminary Results for Ongoing Phase 2 Expansion Study of CX-2029, a First-in-Class Antibody-Drug Conjugate Candidate Targeting the Transferrin Receptor, CD71

20 дек 2021 15:05:00 Источник Nasdaq GlobeNewswire